Nicotine dependence pathway

The nicotine dependence pathway is a complex neurobiological circuit primarily centered on the mesolimbic dopamine system, which mediates the reinforcing and addictive properties of nicotine [3, 4, 12]. Nicotine exerts its effects by binding to neuronal nicotinic acetylcholine receptors (nAChRs), particularly the alpha-4 beta-2 (α4β2) and alpha-7 (α7) subtypes, located on dopaminergic, glutamatergic, and GABAergic neurons [3, 15]. This binding triggers the release of various neurotransmitters, most notably dopamine in the nucleus accumbens, which signals reward and pleasure [4, 16]. Chronic exposure leads to neuroadaptation, including the upregulation of nAChRs and altered synaptic plasticity, resulting in dependence and withdrawal symptoms upon cessation [12, 15, 16]. Therapeutic interventions like varenicline and bupropion target specific components of this pathway to alleviate cravings and block the rewarding effects of smoking [5, 10, 13]. Understanding this pathway is crucial for developing personalized smoking cessation strategies and addressing the global health burden of tobacco use [1, 2, 19].

Other names

Nicotine addiction pathwayTobacco use disorder pathwayMesolimbic dopamine reward pathway

Drugs targeting this pathway primarily act as agonists, partial agonists, or antagonists of nicotinic acetylcholine receptors (nAChRs) to modulate dopamine release in the mesolimbic reward system, thereby reducing withdrawal symptoms and the reinforcing effects of nicotine [3, 5, 10, 13].